Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (12218)	7/28/1998 5:07:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Yes but I understand that until December it is only the ex-Vivus sales staff that are selling muse. Their number is, I think, less than 5%? of the number of Pfizer sales staff - this is the problem. The script numbers don't look too bad graphed on screen if I go out into the hallway and half close my eyes. The wiggles disappear then, and you can see that muse has retained 50% of refills or thereabouts. This means that viagra has only stolen stolen 50%. I think this is important because every muse user capable of doing so will have tried viagra now. If doctors are following Pfizer's directions and advising patients not to combine the two medications, then perhaps I am, as Eddered says, too impatient to see a turnaround in the new scripts. But I feel that Vivus cannot let the patients and doctors sort it out for themselves - they must take a more active role. At least we don't have to worry about Orchid etc. Should be fun when all those Indian chemistry PhDs get going manufacturing sildenafil, apparently it's very easy. I am waiting for some info on ICOS's PDE5 inhibitor. Might be better than sildenafil, less active on PDE6. Will affect viagra sales, not muse presumably. DaiS